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Undertook the analysis of literature, specialist knowledge and clinical experience on treatment options for non-specific vaginal 
inflammations of bacterial, fungal, mixed and unknown aetiology. 
The recommendation presents the current state of knowledge on this subject on the day of the published analysis. Ho-
wever, the expert group reserves the right to update this position in the event of new and significant scientific reports.
INTRODUCTION
Research on the vaginal ecosystem dates back to the 
nineteenth century and is associated with Döderlein’s de-
scription of the role and significance of lactobacilli. These 
gram-positive bacteria were then assigned the role of main-
taining normal vaginal secretions. Further studies have 
shown that other aerobic and anaerobic bacteria are also 
present in the vagina and form the vaginal ecosystem. This 
physiological bacterial flora of the vagina creates a sophis-
ticated and closed ecosystem. It can change depending 
on woman’s age, her hormonal status, especially estrogen, 
sexual activity, performed vaginal procedures, drugs and 
exposure of vaginal mucosa to external substances [1].
Changes in the quantitative and qualitative ratio of the 
vaginal bacterial flora, in the absence of an infective factor, 
were previously called Non-specific Vaginitis (NSV) and are 
now referred to as Bacterial Vaginosis (BV).
Bacterial vaginosis (BV) means changes in vaginal bacte-
rial flora. It consists of the reduction of lactobacillus produ-
cing hydrogen peroxide and an increase of other microor-
ganisms. These include Gram-negative bacteria (Gardnerella 
Vulgaris, Prevotella sp., Atopobium vaginae, Porphiromonas 
spp., Mobiluncus spp., Bacteroides spp. and many other) that 
thrive in the anaerobic environment.
Expansion of Gardnerella colonies leads to the formation 
of a biofilm rich in proteolytic enzymes on the surface of 
epithelial cells, which causes exfoliation of the epithelium 
creating colonisation sites for other anaerobes [1, 2]. 
Vaginal ecosystem changes observed in BV also pre-
dispose to HSV-2, Trichomonas vaginalis, Neisseria gonor-
rhoeae and Chlamydia trachomatis superinfections. The risk 
of HIV infection and transmission increases. Also, chronic BV 
is conducive to the survival of HPV infection, and patients 
have a higher risk of being diagnosed with abnormal cells in 
a cytological examination, and thus, under certain favourable 
conditions, a higher risk of developing CIN. Untreated BV 
predisposes to more frequent infections of the upper floors 
of the genital organ like the endometrium and appendages, 
including fallopian tubes. In pregnant women, BV is a risk 
factor for spontaneous miscarriage or premature delivery [2].
Imbalance in the composition of the vaginal bacterial 
flora, decreased number of Lactobacillus species (Lactobacil-
lus acidophilus L. jensenii, L. brevies, L. Plantarum L. crispatus, 
L. casei, L. fermentum, L. Gasperi) leads to a change in the vaginal 
pH and the possibility of various type of ailment, including 
pathological and symptomatic excessive vaginal discharge.
The dominant symptoms of BV are discharge, often with 
a different colour and smell, discomfort, burning, itching, 
mucosal oedema, and dyspareunia. The clinical picture of 
vaginal infections and biochemical changes depends on 
whether the infection results from aerobic, anaerobic bac-
teria or fungal origin. Vaginal flora abundant for Lactobcilus 
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bacteria results in vaginal pH increase above 6 and an in-
crease of pro-inflammatory cytokines.
Differences in the composition of various elements of 
the human microbiome can lead to functional disorders, 
which may include the genital organs. The microbiome 
has a protective function by competing for nutrients and 
points of adhesion. It can also change with age. The bacte-
rial flora composition can vary depending on the stage of 
life and hormonal status. Vaginal microbiome disorders 
may occur under the influence of antibiotic therapy, during 
menopause, during pregnancy, due to increased exposure 
to microorganisms, the use of hormonal drugs, and im-
munosuppression.
Disorders of the vaginal bacterial flora that change the 
pH of secretions can present with little or no symptoms. In 
these situations, the measurement of vaginal pH is of di-
agnostic importance for early asymptomatic, non-specific 
vaginal inflammation. Abnormal pH should prompt the clini-
cian to implement optimal early therapeutic management.
Based on the aetiology, non-specific vaginal infections 
can be bacterial and non-bacterial.
The most commonly diagnosed bacterial infections are 
BV — (20% to more than 60%, depending on the source), 
followed by Candida-type infections (17%–39%) and in-
fections caused by Trichomonas (4%–30%). Approximately 
every woman, at least once in her life, has a bacterial or 
fungal infection of the vagina [1, 2].
The second group of infections is fungal inflammation, 
with the most common form being candidiasis. Infections 
with other types of fungi occur less often. Candida infections 
are diagnosed based on the symptoms of vaginitis and vulva 
in the presence of the microorganisms mentioned above. 
In the case of fungal infections, Candida albicans accounts 
for 80% to 92% of vaginal and vulvar mycoses.
Diabetes, antibiotic therapy and immunosuppression 
are predisposing factors for the rapid growth of yeast colo-
nies [1].
Factors that cause vaginal infection and subsequent 
symptomatic inflammation may also have a mixed aetiol-
ogy: bacterial-fungal.
Bacteriological smears or cultures are not always availa-
ble for diagnosis or require time to obtain a result. There-
fore, the introduction of treatment before obtaining cul-
ture results is justified for antiseptic drugs. Effectiveness 
of these drugs is described in numerous reports [3, 4]. 
In postmenopausal women, due to a decrease in es-
trogen levels, atrophic genital lesions are common, which 
are the primary cause of developing non-specific vaginal 
inflammation.
Menopausal sex hormone deficiency causes an increase 
in vaginal pH and disappearance of physiological bacte-
rial flora, which consequently increases the susceptibility 
to infections, mainly caused by bacteria migrating from 
the vulva and anal area (Streptococcus sp., Enterococcus sp., 
E. coli). Vaginal swabs have a higher incidence of severe leu-
kocytic reactions and poor exfoliation of epithelial cells. The 
decrease in the physiological vaginal flora coexists with the 
appearance of numerous pathogens. 
In postmenopausal women, Gram-positive cocci are 
2.5 times more common than before menopause. Staph-
ylococcus aureus strains are isolated in bacterial cultures 
(5 times more often than before menopause), Corynebacte-
rium sp., (3 times more often), Streptococcus agalactiae and 
Enterococcus faecalis (2 times more often), E. coli (2 times 
more often), and also K. pneumoniae, P. mirabilis, C. freundii, 
not seen before menopause. Due to lack of glycogen and 
increased pH in the genital tract, strains of Candida albicans 
occur less frequently than in the group of premenopausal 
women [5].
Among the etiological factors of inflammatory vaginosis 
in women of childbearing age, bacterial aetiology remains 
the first, although a significant increase in the percentage 
of fungal infections has been observed in recent years. In 
turn, 1/3 of vaginitis in postmenopausal women has a bac-
terial, fungal or trichomoniasis aetiology. The remaining 
2/3 consist of vaginal atrophy, allergic factors, dermatologi-
cal causes, and general diseases [5].
The standard of management in women with decreased 
estrogen levels is the elimination of inflammation. In the sec-
ond stage by local estrogenization, the vaginal epithelium is 
restored. A similar effect is obtained by using laser vaginal 
revitalisation. This method seems to have particular applica-
tion in women with contraindications for estrogen use [6, 7].
The current recommendations of the Center for Dis-
ease Control and Prevention (CDC) on the treatment of BV 
include treatment with antibiotics and chemotherapeutic 
agents (clindamycin, metronidazole, tinidazole) used orally 
or vaginally. These methods of treatment are associated with 
a reasonably good prognosis in terms of short-term treat-
ment rates, and unfortunately, in the long run, they do not 
prevent recurrence of BV in half of the cases. 
The increasing resistance to antibiotics often used exces-
sively in various forms of vaginitis, increasingly hinders the 
effectiveness of this therapy. Low efficacy of antibiotics has 
lead to limiting their use and replacing with antiseptics as 
the first-line treatment 
It has been proven that the use of typical BV treat-
ment with antibiotics and chemotherapeutic agents 
such as clindamycin and metronidazole, due to the in-
creasingly occurring drug resistance, can be ineffective. 
In one study evaluating the effect of the above treatment on 
30 bacterial strains grown in BV, it was shown that all strains 
tested were resistant to metronidazole and tinidazole, and 
67% were also resistant to clindamycin [8].
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The same is true for fungal infections. Due to the de-
velopment of resistance to fluconazole by Candida, new 
therapeutic options are becoming necessary [9]. Also, new 
information on the structure and function of vaginal colo-
nisation helps explain why antibiotic treatment has only 
limited use in infections involving microbial biofilms. The 
low effectiveness of antibiotics in preventing relapses is 
caused by the inability to eliminate bacteria associated with 
the vaginal biofilm, which is only temporarily suppressed, 
and quickly recovers its activity after stopping treatment. 
Besides, in the case of bacterial inflammatory vaginosis 
(BV), antibiotic treatment is often limited by the patient’s 
general condition, and side effects associated with systemic 
administration may occur. 
Therefore, in BV cases it is necessary to consider the 
forms of treatment known before the antibiotic era, but 
in a new technological edition using the achievements of 
modern pharmaceutical technologies, i.e. the use of vaginal 
antiseptics [2, 10]. 
Modern antiseptics are an alternative to antibiotic treat-
ment, provided they combine a broad antimicrobial spec-
trum with low toxicity and high tissue biocompatibility. 
Topical antiseptics should now be the first choice in the 
treatment of local microbial vaginal infections. 
Therefore, new antimicrobial agents that will act in a tar-
geted manner without drug resistance and elimination of bi-
ofilm should dominate BV treatment as a first-line approach.
A full arsenal of vaginal products is available. They are 
tested for efficacy and safety in the treatment of non-specific 
inflammation of the vagina: BV, candidiasis or viral infections. 
They include:
 Ū Polyhexamethylene biguanide (poliheksanid, PHMB) 
[2, 11–28],
 Ū Dequaline chloride [2, 5, 19, 20, 25, 29, 31, 32],
 Ū Povidone iodine [33, 34], 
 Ū Sliver ions [26, 30, 35–40],
 Ū Boric acid [41–45], 
 Ū Chlorhexidine [46–48],
 Ū Lactic acid bacteria with or without estriol [49, 50].
BRIEF DESCRIPTION OF AVAILABLE 
ANTISEPTIC COMPOUNDS USED IN THE 
TREATMENT OF INFLAMMATORY VAGINOSIS 
OF VARIOUS ETIOLOGIES
Polyhexamethylene biguanide (poliheksanid, 
PHMB)
Polyhexanide is an antiseptic with a broad spectrum 
of antimicrobial activity, including Gram-positive and 
Gram-negative bacteria, including MRSA, VRE, Escherichia 
coli, Pseudomonas aeruginosa, HPV, HSV-1, HIV viruses fungi 
(Candida albicans and others), protozoa causing keratitis 
(Acanthamoeba) [2, 11–13].
PHMB has three mechanisms of action:
 Ū blocks adhesion of microorganisms to surfaces [11, 14, 15],
 Ū increases the liquidity and permeability of the bacterial 
cell membrane, which leads to a loss of its integrity and 
ultimately to cell death [11, 16–19],
 Ū inhibits the metabolism of bacterial cells, has a higher 
efficiency in an environment with pathologically el-
evated pH, and effectively prevents the re-emergence 
of biofilm [11, 19-22].
PHMB does not generate bacterial resistance and re-
duces the number of bacteria.
PHMB has Lactobacillus spp. sparring effects due to 
differences in cell- wall binding [23].
Polyhexanide (PHMB) has good efficacy and safety in the 
topical application in the treatment of non-specific vaginal 
infections of bacterial, fungal, viral and mixed aetiology as 
well as perioperative prophylaxis before vaginal procedures 
[24]. No adverse effects were found even with prolonged 
use, and the frequency of allergies is low [25, 26].
There are preliminary reports of the effectiveness of 
the treatment in doubtful cases and a small degree of cyto-
logical abnormalities in combination with an existing HPV 
infection. The above statements are very promising and 
may form the basis for further research in this direction [27].
PHMB summary
1. When used vaginally, PHMB has no inhibitory effects on 
Lactobacillus spp. growth [23].
2. The effectiveness of treatment without bacterial resist-
ance and the elimination of biofilm [2, 20].
3. Good tolerability with a small number of side effects even 
with prolonged use, low rate of allergic reactions [25, 26].
4. There is no convincing evidence of safety in pregnancy [28].
Dequalinium chloride
Dequalinium chloride as a quinoline derivative with 
a broad spectrum of biological activity, including antibacte-
rial activity. It is used to treat vaginitis of bacterial, fungal, 
mixed and unknown aetiology [5].
It shows a broad spectrum of antibacterial activity 
against aerobic Gram-positive bacteria (Enterococcus faecalis 
Lactobacillus spp., Staphylococcus aureus, Streptococcus aga-
lactiae, Streptococcus pyogenes), Gram-negative (Enterobacter 
spp., Escherichia coli, Klebsiella spp. Spp.), anaerobic bacteria 
(Bacteroides spp., Fusobacteria, Gardnerella vaginalis, Prevo-
tella spp., Peptostreptococci, Poryphyromonas spp.) [19, 20, 29]. 
Clinical studies report its use in the treatment of vaginal 
inflammation in pregnant women (in all trimesters) and 
during lactation [2, 25].
This compound shows activity between 24 and 72 hours 
after the first dose.
Treatment usually lasts about six days.
435
Mariusz Zimmer et al., Polish Society of Gynecologists and Obstetricians recommendation on the use of antiseptics
www. journals.viamedica.pl/ginekologia_polska
Summary — dequaline chloride
1. Efficacy in the treatment of BV.
2. Good tolerance - side effects occur at a frequency of 
7.8% and may include mainly vaginal candidiasis, vagi-
nal discharge, vulva and vaginal itching, and burning 
sensation within the vulva and vagina [29, 31, 32].
3. Due to the chemical nature of the substance - a quater-
nary ammonium compound, anionic substances such 
as soaps, detergents and surfactants, may additionally 
weaken the antibacterial effect of dequalinium chloride. 
Therefore, concomitant use of soaps, spermicides or 
irrigation is not recommended [29, 31, 32].
4. The manufacturer declares the possibility of use in preg-
nant women (in all trimesters) and during lactation [29].
5. It is contraindicated in cases of ulceration of the vaginal 
epithelium and vaginal part of the cervix, and in girls 
who have not yet started menstruation, i.e. have not 
reached [29, 31].
Povidone-iodine
Iodopovidone (povidone-iodine) is characterised by 
a broad spectrum of action against Gram-positive bacteria, 
including strains of Lactobacillus spp., and Gram-negative 
bacteria, bacterial spores, viruses, protozoa, as well as fungi 
and yeast [33]. 
The main application according to Kramer’s study is 
the use in disinfection of the surgical field, puncture sites, 
puncture, catheterisation, blood collection and as an active 
agent for short-term disinfectant use [34]. 
In the form of vaginal globules, it can be used in vari-
ous types of vaginal inflammation, especially in bacterial 
vaginitis caused by Gardnerella vaginalis or infections by 
vaginal trichomes (Trichomonas vaginalis) [33]. It is used in 
the prevention of infections before surgical and diagnostic 
procedures within the vagina.
Due to the risk of thyroid dysfunction, povidone-iodine, 
in all forms of use, has additional restrictions, i.e.
 Ū it should not be used for more than seven days,
 Ū use before and after radioiodine treatment is contrain-
dicated,
 Ū combined use with octenidine and/or silver in the form 
of vaginal globules is contraindicated.
Summary — povidone-iodine
1. One-time preparation of the operating field — rinsing 
the vagina before the vaginal procedure.
2. Preparation of the vagina before vaginal surgery in the 
form of vaginal globules.
Silver ions
The antiseptic mechanism of silver ions is to inhibit cell 
division, damage the bacterial cell membrane, disruption 
transport in the cell, which leads to its death. Silver, as a lo-
cal antiseptic, has a different mechanism of action from 
antibiotics and multidirectional effect on a bacterial cell, 
which means that the likelihood of developing resistance 
to silver is very low [35, 36].
The creation of TIAB silver, i.e. titanium dioxide particles 
on which active nanoparticles of Ag + silver ions have been 
deposited, in combination with benzalkonium chloride, has 
allowed an increase in antimicrobial and antiviral activity. The 
TIAB molecule is characterised by increased stability com-
pared to other antiseptics based on silver compounds [30, 37].
Silver in the TIAB molecule is effective against such mi-
croorganisms as: Staphylococcus aureus, Escherichia coli, Pseu-
domonas aeruginosa, Acinetobacter baumannii, Klebsiella pneu-
moniae, Neisseria gonorrhoeae, Enterococcus faecalis, Listeria 
monocytosis, Streptomidisis, Gardneidcus) Chlamydia trachoma-
tis. Besides, the spectrum of this form of silver also includes 
pathogens characterised by high antibiotic resistance, includ-
ing staphylococci (MRSA) and vancomycin-resistant entero-
cocci (VRE) and prevents the formation of bacterial biofilm.
Compounds containing the TIAB silver complex may also 
be recommended for patients with an abnormal low-grade 
cytological test or a low-grade ASC-US and L-SIL lesion. 
The mixture is useful in the treatment of inflammation and 
abnormal cytological smears [26, 38].
This compound is also characterised by high activity 
against yeast-like fungi: Candida albicans, Candida glabrata 
and mould — Aspergillus niger.
It has also been shown that it helps combat viral infec-
tion by showing antiviral activity, among others influenza 
(A / H1N1), polio, cytomegalovirus, smallpox, herpes zoster, 
HIV, HSV-1, HSV-2, hepatitis A, B, E, rubella, adenoviruses, 
herpes, mumps, enteroviruses, rhinoviruses, astroviruses 
or coronaviruses [37, 39, 40].
There are preliminary reports on the beneficial effects 
of silver compounds in the treatment of HPV infection. This 
requires further evaluation and validation of prospective 
studies involving a more significant number of people [26].
Summary — silver ions
1. Effectiveness in the treatment of bacterial infections, 
including those characterised by antibiotic resistance, 
including Staphylococcus (MRSA) and vancomycin-re-
sistant enterococci (VRE). 
2. A broad spectrum of anti-inflammatory properties in-
cluding antifungal activity.
3. Possibility of use in II/III trimester of pregnancy.
4. Good tolerance and safety when applied locally.
Boric acid
Boric acid (Boric acid borax, orthoboric acid) - an in-
organic chemical compound in the form of a weak acid 
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(Acidum boricum). In nature, it can be found in some plants, 
in sea salts and minerals (e.g. in sassoline) [41].
The mechanism of bactericidal and fungistatic activity 
of boric acid is not fully understood. The bactericidal and 
fungistatic effect of boric acid is believed to be through 
penetration through the cell wall, and damage to the cell 
membrane of fungi [42]. 
The effectiveness of boric acid in the treatment of vaginal 
infections caused by Candida albicans has been proven [43] 
Boric acid products are also drugs of choice in the treatment 
of acute and recurrent fungal vaginitis and vulva caused by 
fungal species other than Candida albicans [44, 45].
Due to its unique drying, astringent and antiseptic prop-
erties, and low per cent solution, it is used as a disinfectant 
and to promote granulation in wound healing.
Boric acid in the form of vaginal globules is useful espe-
cially in the treatment of vaginitis caused by infection with 
C.glabrata and C.krusei.
Summary — boric acid
1. Maintenance therapy of especially fungal vaginosis and 
recurrent infections
2. Prophylaxis of BV in patients with risk factors, especially 
during antibiotic therapy and hypoestrogenism.
Chlorhexidine
Chlorhexidine is a substance that has antibacterial activ-
ity. It damages the cell membrane of bacteria, which in turn 
leads to an increase in its permeability and cell breakdown.
Chlorhexidine has a strong bactericidal effect on 
Gram-positive bacteria, and less strongly on Gram-negative 
bacteria [46, 47]. 
Chlorhexidine resistance is observed for some path-
ogens such as methicillin-resistant S. aureus, as well as 
P. aeruginosa and A. Baumannie. In the treatment of bacterial 
vaginosis, chlorhexidine can be used vaginally.
Compared to standard therapies, topical treatment of 
bacterial vaginosis with chlorhexidine is characterszed by 
a low frequency of side effects [48].
Summary — chlorhexadin
1. Efficacy in the treatment of BV.
2. Element of prevention and supportive therapy before 
and after gyanecological surgical procedures.
Lactic acid bacteria with or without estriol
The administration of lactobacilli is intended to restore 
the physiological bacterial flora after topical or systemic 
treatment with anti-infectious agents or chemotherapeutic 
agents.
The combination of administration of the above lacto-
bacilli with estriol increases the regenerative effect on the 
vagina, especially on its atrophic inflammation in the period 
of menopause and supportive therapy in menopausal hor-
mone therapy (HTM). 
The mechanism of action is based on strengthening the 
vaginal ecosystem after anti-infectious treatment by exog-
enous use of live lactic acid bacteria. There is no evidence 
of an adverse effect on the pregnancy or the condition of 
the fetus/newborn. Lactobacilli can be used in pregnancy, 
while a compound containing a combination of Lactobacil-
lus acidophilus and estriol can be used during pregnancy 
with more significant benefit for the patient than the risk 
related to estrogen activity [49].
Summary — lactic acid bacteria with or without 
estriol
1. Used in the second stage of anti-inflammatory treat-
ment as maintenance therapy.
2. To support that development of physiological vaginal 
flora in recurrent inflammation after treatment with 




The treatment of vaginal infections with non-anti-
biotic compounds is an effective method, especially in 
the case of BV, and can be successfully used as a first-line 
treatment instead of antibiotic therapy carrying pos-
sible complications and the risk of antibiotic resistance.
REFERENCES
1. Rekomendacje Polskiego Towarzystwa Ginekologicznego. Ginekol Pol. 
2014; 85: 557–559.
2. Bacterial Biofilms. Current Topics in Microbiology and Immunology. 
2008, doi: 10.1007/978-3-540-75418-3.
3. Weissenbacher ER, Donders G, Unzeitig V, et al. Fluomizin Study Group. 
A comparison of dequalinium chloride vaginal tablets (Fluomizin®) 
and clindamycin vaginal cream in the treatment of bacterial vaginosis: 
a single-blind, randomized clinical trial of efficacy and safety. Gynecol 
Obstet Invest. 2012; 73(1): 8–15, doi: 10.1159/000332398, indexed in 
Pubmed: 22205034.
4. Menard JP. Antibacterial treatment of bacterial vaginosis: current and 
emerging therapies. International Journal of Women’s Health. 2011: 295, 
doi: 10.2147/ijwh.s23814.
5. Sobczuk A, et al. Stany zapalne pochwy u kobiet w wieku menopauzal-
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